## Timothy J Henrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5594510/publications.pdf

Version: 2024-02-01

93 5,211 35 67 g-index

106 106 106 106 6903

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	15.2	395
2	HIV-1 persistence in CD4+ T cells with stem cell–like properties. Nature Medicine, 2014, 20, 139-142.	15.2	379
3	Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation. Annals of Internal Medicine, 2014, 161, 319.	2.0	370
4	Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases, 2013, 207, 1694-1702.	1.9	250
5	Clinical Risk Factors for Severe <i>Clostridium difficile</i> –associated Disease. Emerging Infectious Diseases, 2009, 15, 415-422.	2.0	204
6	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	3.9	186
7	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 224, 1839-1848.	1.9	176
8	Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. Scientific Reports, 2014, 4, 4116.	1.6	144
9	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Reports, 2021, 36, 109518.	2.9	142
10	Differential decay of intact and defective proviral DNA in HIV-1 $\hat{a}$ e"infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	2.3	140
11	Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. Journal of Virological Methods, 2012, 186, 68-72.	1.0	133
12	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells, 2021, 10, 386.	1.8	125
13	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infectious Diseases, 2015, 2, ofv123.	0.4	119
14	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	4.7	117
15	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nature Biotechnology, 2021, 39, 928-935.	9.4	106
16	HIV-1 entry inhibitors: recent development and clinical use. Current Opinion in Virology, 2013, 3, 51-57.	2.6	105
17	SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV,the, 2021, 8, e334-e341.	2.1	99
18	Emerging Technologies for Point-of-Care Management of HIV Infection. Annual Review of Medicine, 2015, 66, 387-405.	5.0	97

#	Article	IF	CITATIONS
19	Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. Journal of NeuroVirology, 2021, 27, 191-195.	1.0	95
20	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathogens, 2016, 12, e1005535.	2.1	85
21	Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. Journal of Leukocyte Biology, 2021, 110, 21-26.	1.5	82
22	Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathogens, 2018, 14, e1006856.	2.1	70
23	Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring. Advanced Drug Delivery Reviews, 2016, 103, 90-104.	6.6	66
24	SARSâ€CoVâ€⊋ and Mitochondrial Proteins in Neuralâ€Derived Exosomes of COVIDâ€19. Annals of Neurology, 2022, 91, 772-781.	2.8	63
25	Xenotropic Murine Leukemia Virus–Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions. Journal of Infectious Diseases, 2010, 202, 1478-1481.	1.9	60
26	Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. American Journal of Transplantation, 2020, 20, 3225-3233.	2.6	60
27	Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE) Tj ETQq1 1 0.784314 rg States of America, 2015, 112, E4354-63.	BT /Overlo 3.3	ock 10 Tf 50 56
28	Tunable Fanoâ∈Resonant Metasurfaces on a Disposable Plasticâ∈Template for Multimodal and Multiplex Biosensing. Advanced Materials, 2020, 32, e1907160.	11.1	56
29	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases, 2022, 9, ofab640.	0.4	56
30	Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild <scp>COVID</scp> â€19. Annals of Clinical and Translational Neurology, 2022, 9, 221-226.	1.7	53
31	High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. EBioMedicine, 2017, 20, 217-229.	2.7	50
32	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Annals of Oncology, 2018, 29, 2141-2142.	0.6	47
33	Treatment of immunocompromised COVIDâ€19 patients with convalescent plasma. Transplant Infectious Disease, 2021, 23, e13477.	0.7	47
34	Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL. PLoS ONE, 2012, 7, e50065.	1.1	45
35	A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads. Virology, 2017, 507, 135-139.	1.1	43
36	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. Clinical Infectious Diseases, 2022, 75, e916-e919.	2.9	42

#	Article	IF	Citations
37	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. Journal of Infectious Diseases, 2017, 216, 254-262.	1.9	41
38	Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	41
39	Defining cerebrospinal fluid HIV RNA escape. Aids, 2019, 33, S107-S111.	1.0	40
40	Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIVâ€1 Response to Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 51, 93-98.	2.9	30
41	HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug. Journal of Virology, 2012, 86, 1119-1128.	1.5	29
42	Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 î"32. Aids, 2015, 29, 867-876.	1.0	26
43	Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. Scientific Reports, 2015, 5, 9919.	1.6	25
44	Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight, 2022, 7, .	2.3	24
45	Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 420-427.	0.9	23
46	Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-l ${\rm ^{\circ}}B$ signaling. JCI Insight, 2022, 7, .	2.3	23
47	Ethics of ART interruption after stem-cell transplantation. Lancet HIV, the, 2016, 3, e8-e10.	2.1	20
48	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nature Communications, 2022, 13, 1219.	5.8	20
49	Early Treatment and HIV-1 Reservoirs: A Stitch in Time?. Journal of Infectious Diseases, 2013, 208, 1189-1193.	1.9	19
50	Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. Journal of Histochemistry and Cytochemistry, 2018, 66, 427-446.	1.3	19
51	Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. Clinical Infectious Diseases, 2022, 74, 2083-2084.	2.9	19
52	Association of Alcohol Abuse and Injection Drug Use with Immunologic and Virologic Responses to HAART in HIV-positive Patients from Urban Community Health Clinics. Journal of Community Health, 2008, 33, 69-77.	1.9	18
53	Lymphoma Diagnosis and Plasma Epsteinâ€Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211. Clinical Infectious Diseases, 2009, 48, 642-649.	2.9	18
54	Infectious Granulomatous Dermatitis Associated With Rothia mucilaginosa Bacteremia: A Case Report. American Journal of Dermatopathology, 2010, 32, 175-179.	0.3	18

#	Article	IF	Citations
55	Seeing Is Believing: Nuclear Imaging of HIV Persistence. Frontiers in Immunology, 2019, 10, 2077.	2.2	17
56	Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid organ transplant recipients. Journal of Clinical Investigation, $2021,131,.$	3.9	17
57	Geographic dynamics of viral encephalitis in Thailand. Microbes and Infection, 2003, 5, 603-611.	1.0	15
58	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. Pathogens and Immunity, 2019, 4, 147.	1.4	15
59	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Translational Research, 2022, 241, 1-12.	2.2	15
60	Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Advances, 2018, 2, 3479-3482.	2.5	14
61	HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility. Journal of Virology, 2020, 94, .	1.5	14
62	Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. American Journal of Transplantation, 2021, 21, 1765-1779.	2.6	14
63	Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity <i>Ex Vivo</i> and <i>In Vivo</i> Journal of Virology, 2021, 95, .	1.5	13
64	Hantaan virus antibody prevalence in rodent populations of several provinces of northeastern Thailand. Tropical Medicine and International Health, 2002, 7, 840-845.	1.0	12
65	SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses. PLoS ONE, 2011, 6, e28047.	1.1	12
66	Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. Journal of Infectious Diseases, 2020, 221, 1146-1155.	1.9	11
67	Impact of Age, Gender, and Pregnancy on Syphilis Screening Using the Captia Syphilis-G Assay. Sexually Transmitted Diseases, 2011, 38, 1126-1130.	0.8	10
68	CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 766-770.	1.9	10
69	Rapid development of HIV elite control in a patient with acute infection. BMC Infectious Diseases, 2019, 19, 815.	1.3	10
70	Total-Body PET Imaging in Infectious Diseases. PET Clinics, 2021, 16, 89-97.	1.5	9
71	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. Open Forum Infectious Diseases, 2021, 8, ofaa531.	0.4	9
72	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. International Journal of Behavioral Medicine, 2022, 29, 610-623.	0.8	9

#	Article	IF	Citations
73	From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation. Current HIV/AIDS Reports, 2020, 17, 385-393.	1.1	8
74	Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists. Antimicrobial Agents and Chemotherapy, 2012, 56, 1931-1935.	1.4	7
75	Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infectious Diseases, 2014, 1, ofu018.	0.4	7
76	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. PLoS ONE, 2018, 13, e0197298.	1.1	6
77	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 2020, 6, 19-26.	0.3	6
78	A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, 73, e2845-e2846.	2.9	6
79	Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus–infected rhesus macaques on antiretroviral therapy. Journal of Clinical Investigation, 2022, 132, .	3.9	5
80	COVIDâ€19 in vaccinated versus unvaccinated hematologic malignancy patients. Transplant Infectious Disease, 2022, 24, .	0.7	4
81	Dolutegravir intensification and HIV persistence: 3â€^+â€^1â€^=â€^3. Lancet HIV,the, 2018, 5, e201-e202.	2.1	3
82	Progress towards obtaining an HIV cure. Current Opinion in HIV and AIDS, 2018, 13, 381-382.	1.5	3
83	Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infectious Diseases, 2021, 8, ofab393.	0.4	3
84	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 2020, 6, 19-26.	0.3	3
85	HIV eradication: is cord blood the answer?. Lancet HIV,the, 2015, 2, e219-e220.	2.1	2
86	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Advances, 2018, 2, 1412-1416.	2.5	2
87	TNF-alpha inhibition in the setting of undiagnosed HIV infection. Aids, 2021, Publish Ahead of Print, 2163-2168.	1.0	2
88	Response to Shen and Siliciano. Clinical Infectious Diseases, 2010, 51, 1106-1107.	2.9	1
89	Second example reported of a stem-cell transplant in the clinic leading to HIV remission. Nature, 2019, 568, 175-176.	13.7	1
90	Biosensing: Tunable Fanoâ€Resonant Metasurfaces on a Disposable Plasticâ€Template for Multimodal and Multiplex Biosensing (Adv. Mater. 19/2020). Advanced Materials, 2020, 32, 2070151.	11.1	1

## TIMOTHY J HENRICH

#	Article	IF	CITATIONS
91	Rapid sequential development and rupture of mycotic aneurysms within a period of days in a patient with graft-versus-host disease and angiotropic <i>Scedosporium apiospermum</i> infection., 0, 13, 242.		1
92	A Woman with Dyspnea and Altered Mental Status. New England Journal of Medicine, 2016, 374, e29.	13.9	0
93	CE-541-04 CARDIAC ARRHYTHMIAS IN POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION ASSESSED BY AMBULATORY RHYTHM MONITORING. Heart Rhythm, 2022, 19, S54-S55.	0.3	0